780769-39-3

Basic information

• Product Name: 2,2-difluoro-2-(5-methylpyridin-2-yl)ethanol
• CAS NO: 780769-39-3
• Molecular Weight: 173.162
• Mol File: 780769-39-3.mol

Chemical Properties

• CAS DataBase Reference: 2,2-difluoro-2-(5-methylpyridin-2-yl)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-difluoro-2-(5-methylpyridin-2-yl)ethanol(780769-39-3)
• EPA Substance Registry System: 2,2-difluoro-2-(5-methylpyridin-2-yl)ethanol(780769-39-3)

Safety Data

• Hazardous Substances Data: 780769-39-3(Hazardous Substances Data)

Usage

Fluoroalkyl compound

A type of organic compound containing an alkyl group bonded to one or more fluorine atoms.

Substituted pyridine ring

A pyridine ring (a six-membered aromatic ring with one nitrogen atom) that has other functional groups attached to it, in this case, fluoroalkyl and ethanol groups.

Pharmaceutical industry use

The compound is primarily used as a building block for the synthesis of various medicinal compounds.

Potential applications

The compound has a variety of potential applications, including as an intermediate in the production of agrochemicals, pharmaceuticals, and other fine chemicals.

Hazardous properties

Due to its potential hazardous properties, the compound must be handled and used with caution.

Safety protocols and regulations

Proper handling and usage of the compound must follow all safety protocols and regulations to ensure safe and responsible use.

Upstream product

• 503627-67-6 2,2-difluoro-2-(5-methylpyridine-2-yl)acetic acid ethyl ester 
• 294181-95-6 2-(5-bromopyridine-2-yl)-2,2-difluoroacetic acid ethyl ester 
• 3510-66-5 2-Bromo-5-methylpyridine 

Relevant articles and documents

PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS

Disclosed are chemical entities of formula I: [INSERT CHEMICAL FORMULA HERE] wherein X, Y, Z, R1, R3, R4, R5 and R6 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of formula I, and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of formula I.

DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS

Disclosed are chemical entities of formula (I) wherein X, Y, Z, R1, R3, R4, R5 and R6 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of formula I.

Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif

2-Cyano-6-fluorophenylacetamide was explored as a novel P2 scaffold in the design of thrombin inhibitors. Optimization around this structural motif culminated in 14, which is a potent thrombin inhibitor (Ki = 1.2 nM) that exhibits robust effica

OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION

This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also rela

Substituted phenyl acetamides and their use as protease inhibitors

Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, R11, B, Y and W are set forth in the specification. The compound

SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS

Phenyl acetamide compounds are described, including compounds of Formula (I): or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, R11, B, Y and W are set forth in the specification. The compou